Replies to post #376 on Acasti Pharma, Inc (ACST)

[keekee]

Here's the current state of facts, more update soon I guess:

CaPre is designed to modulate the unhealthy levels of the major lipids that can be associated with cardio-metabolic disease. In four clinical trials conducted to date, Acasti saw the following beneficial effects with CaPre:

Significant reduction of triglycerides and non-high density lipoprotein cholesterol (non-HDL-C) levels in the blood of patients with mild to severe hypertriglyceridemia;
No deleterious effect on low-density lipoprotein cholesterol, or "bad" cholesterol (LDL-C), and potential to reduce LDL-C;
Potential to increase high-density lipoprotein cholesterol, or "good" cholesterol (HDL-C);
Good bioavailability without significant food effect, important considerations for patients with metabolic disease who should be on a low fat diet and;
An overall safety profile similar to that of currently marketed omega-3s, with the added potential for beneficial LDL-C effect.